Hodgkin disease survival in Europe and the US - Prognostic significance of morphologic groups

被引:51
作者
Allemani, Claudia
Sant, Milena
De Angelis, Roberta
Marcos-Gragera, Rafael
Coebergh, Jan Willem
机构
[1] Ist Nazl Studio & Cura Tumori, Dept Prevent & Predict Med, Epidemiol Unit, I-20133 Milan, Italy
[2] Ist Super Sanita, Dept Canc Epidemiol, Natl Ctr Epidemiol Surveillance & Hlth Promot, I-00161 Rome, Italy
[3] Eindhoven Canc Registry, Comprehens Canc Ctr S, Eindhoven, Netherlands
关键词
Hodgkin disease; population cancer registries; relative survival; morphology; Europe; US;
D O I
10.1002/cncr.21995
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The survival of patients with Hodgkin disease (HD) varies markedly across Europe and generally is shorter than the survival of patients in the U.S. To investigate these differences, the authors compared population-based HD survival in relation to morphologic type among populations in Europe and the U.S. METHODS. The authors analyzed 6726 patients from 37 cancer registries that participated in EUROCARE-3 and 3442 patients from 9 U.S. Surveillance, Epidemiology, and End Results (SEER) registries. Patients were diagnosed during 1990 to 1994 and were followed for at least 5 years. The European registries were grouped into EUROCARE West, EUROCARE UK, and EUROCARE East. Morphologic groups were nodular sclerosis, mixed cellularity, lymphocyte depletion, lymphocyte predominance, and not otherwise specified (NOS). The influence of morphology on geographic differences in 5-year relative survival was explored by using multiple regression analysis. RESULTS. In the model that was adjusted by age, gender, and years since diagnosis, the relative excess risk (RER) of death was 0.93 (95% confidence interval [95% CI], 0.81-1.05) in EUROCARE West, 1.15 (95% CI, 1.04-1.28) in EUROCARE UK, and 1.39 (95% CI, 1.21-1.60) in EUROCARE East (compared with the SEER data). When morphology was included, EUROCARE UK and SEER no longer differed (RER, 1.06; 95% CI, 0.95-1.18). Morphology distribution varied markedly across Europe and much less in the U.S., with nodular sclerosis less common in Europe (45.9%) than the U.S.(61.7%). The RER data showed that patients who had lymphocyte depletion, NOS, and mixed cellularity had a significantly worse prognoses compared with patients who had nodular sclerosis, whereas patients who had lymphocyte predominance had the best prognosis. CONCLUSIONS. The current results provide population-based evidence that morphology strongly influences the prognosis of patients with HD. However differences in the morphologic case mix explains only some of the geographic variations observed in survival.
引用
收藏
页码:352 / 360
页数:9
相关论文
共 40 条
[1]  
[Anonymous], 1995, IARC SCI PUBLICATION
[2]   Trend of cervical cancer mortality in Belgium (1954-1994): Tentative solution for the certification problem of unspecified uterine cancer [J].
Arbyn, M ;
Geys, H .
INTERNATIONAL JOURNAL OF CANCER, 2002, 102 (06) :649-654
[3]   Epstein-Barr virus and Hodgkin's disease: Further evidence for the three disease hypothesis [J].
Armstrong, AA ;
Alexander, FE ;
Cartwright, R ;
Angus, B ;
Krajewski, AS ;
Wright, DH ;
Lee, F ;
Kane, E ;
Jarrett, RF .
LEUKEMIA, 1998, 12 (08) :1272-1276
[4]  
BONADONNA G, 2003, MED ONCOLOGICA, P1275
[5]   Age-specific survival after Hodgkin's disease in a population-based cohort (United States) [J].
Clarke, CA ;
Glaser, SL ;
Prehn, AW .
CANCER CAUSES & CONTROL, 2001, 12 (09) :803-812
[6]   COMBINATION CHEMOTHERAPY IN TREATMENT OF ADVANCED HODGKINS DISEASE [J].
DEVITA, VT ;
SERPICK, AA ;
CARBONE, PP .
ANNALS OF INTERNAL MEDICINE, 1970, 73 (06) :881-+
[7]   Regression models for relative survival [J].
Dickman, PW ;
Sloggett, A ;
Hills, M ;
Hakulinen, T .
STATISTICS IN MEDICINE, 2004, 23 (01) :51-64
[8]   Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's disease [J].
Diehl, V ;
Sextro, M ;
Franklin, J ;
Hansmann, ML ;
Harris, N ;
Jaffe, E ;
Poppema, S ;
Harris, M ;
Franssila, K ;
van Krieken, J ;
Marafioti, T ;
Anagnostopoulos, I ;
Stein, H .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :776-783
[9]  
ERDKAMP FL, 1992, CANCER, V70, P830, DOI 10.1002/1097-0142(19920815)70:4<830::AID-CNCR2820700418>3.0.CO
[10]  
2-X